-
Press Release
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
-
Story
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond -
Press Release
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
-
Press Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
-
Press Release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
-
Story
Bringing proteins together to take cancer apart -
Press Release
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
-
Press Release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
-
Press Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Press Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Press Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Press Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population